secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001356576-23-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q4/FY2022: total rev $667.2M (+15% YoY); Qelbree sales $61.3M; FY2023 rev guidance $580-620M
--------------------------------------------------------------------------------

- Full year 2022 total revenues $667.2M (+15% YoY); Q4 net product sales $163.8M (+6% vs Q4 2021).
- Qelbree net sales $61.3M in FY2022 (vs $9.9M in FY2021); GOCOVRI $104.4M (+19% vs FY2021).
- GAAP diluted EPS $1.04 for FY2022 (Q4: $0.43); non-GAAP operating earnings $148.8M.
- FY2023 revenue guidance $580-620M (excl. Trokendi XR), ~30% growth; non-GAAP op earnings $65-95M.
- Cash $555.2M at Dec 2022; $150M credit line from UBS; SPN-830 FDA meeting April 2023; SPN-820 Phase II ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/supn-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer